 Centogene N.V. CNTG, a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that its Supervisory Board member Christoph Ehlers has resigned from office, effective June 15, 2020. After serving more than six years as member of the Companys Supervisory Board, Mr. Ehlers has decided to step down due to personal circumstances. We are extremely grateful to Christoph for his contributions to CENTOGENE as both a member of the Supervisory Board and one of our initial stakeholders, states Prof. Arndt Rolfs, CEO of CENTOGENE. 